Colorectal Cancer (CRC) Active Not Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Active Not Recruiting	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04432857	AN0025 and Pembrolizumab Combination in Advanced Solid Tumors	Treatment	Palupiprant (DB21421) Pembrolizumab (DB09037)
NCT06607185	A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors	Treatment	Carboplatin (DB00958) Cetuximab (DB00002) Cisplatin (DB00515) Fluorouracil (DB00544) Gemcitabine (DB00441) Irinotecan (DB00762) LY4066434 (DB22727) Leucovorin (DB00650) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pembrolizumab (DB09037) Pemetrexed (DB00642)
NCT05787587	A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors	Treatment	IDE-161 (DB25517) Pembrolizumab (DB09037)
NCT05704985	Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors	Treatment	Capecitabine (DB01101) Carboplatin (DB00958) DK210 (DB24308) Fluorouracil (DB00544) Nivolumab (DB09035) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pembrolizumab (DB09037)
NCT05620134	Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer	Treatment	Lenvatinib (DB09078) Pembrolizumab (DB09037)
NCT05581004	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors	Treatment	Atezolizumab (DB11595) Pembrolizumab (DB09037) RO7502175 (DB17502)
NCT04913337	Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies	Treatment	NGM707 (DB28351) Pembrolizumab (DB09037)
NCT03872947	A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors	Treatment	Bevacizumab (DB00112) Carboplatin (DB00958) Cisplatin (DB00515) Fluorouracil (DB00544) Gemcitabine (DB00441) Imiquimod (DB00724) Irinotecan (DB00762) Leucovorin (DB00650) Nivolumab (DB09035) Paclitaxel (DB01229) Pegylated doxorubicin (DB32018) Pembrolizumab (DB09037) Ramucirumab (DB05578) TRK-950 (DB22441)
NCT03657641	Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer	Treatment	Pembrolizumab (DB09037) Regorafenib (DB08896)
NCT04083599	GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors	Treatment	Carboplatin (DB00958) Cisplatin (DB00515) Fluorouracil (DB00544) GEN1042 (DB22466) Gemcitabine (DB00441) Paclitaxel (DB01229) Pembrolizumab (DB09037) Pemetrexed (DB00642)
NCT04585035	Study to Evaluate D-1553 in Subjects With Solid Tumors	Treatment	Cetuximab (DB00002) D-1553 (DB24408) Pembrolizumab (DB09037)
NCT05838768	Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.	Treatment	HRO761 (DB24029) Irinotecan (DB00762) Pembrolizumab (DB09037)